Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company that develops, acquires and commercializes prescription products in respiratory and dermatology markets. Founded in 2004 and headquartered in Vancouver, British Columbia, the company focuses on in-licensing established therapies and launching them under its own commercial infrastructure in North America.
In the respiratory segment, Cipher markets generic inhalation therapies for conditions such as asthma and chronic obstructive pulmonary disease (COPD). These include dry-powder inhalers (DPIs) and metered-dose inhalers (MDIs) that offer patients lower-cost alternatives to branded drugs. In dermatology, the company has brought to market treatments addressing acne, fungal infections of the nails and other skin disorders, often through licensing agreements with innovator companies.
Cipher operates primarily in Canada and the United States. Its business model emphasizes strategic partnerships and licensing arrangements, enabling the company to secure exclusive Canadian rights to new products while collaborating with third-party partners for U.S. commercialization. This approach allows Cipher to leverage established regulatory approvals and focus resources on market access, sales and marketing.
Looking ahead, Cipher continues to expand its product pipeline through in-licensing and development of both generic and branded prescription drugs. The company is advancing new formulations in respiratory care and exploring additional dermatology assets, aiming to build a diversified specialty pharmaceutical portfolio that delivers growth through product launches and ongoing royalty streams.
AI Generated. May Contain Errors.
